Render Target: STATIC
Render Timestamp: 2024-11-21T13:16:35.647Z
Commit: 5c4accf06eb7154018ba3f54329c7590f97f534a
XML generation date: 2024-09-20 06:18:33.004
Product last modified at: 2024-10-22T22:45:07.430Z
1% for the planet logo
PDP - Template Name: Polyclonal Antibody
PDP - Template ID: *******59c6464

Eg5 Antibody #7625

Filter:
  • WB
  • IP

    Supporting Data

    REACTIVITY H
    SENSITIVITY Endogenous
    MW (kDa) 120
    SOURCE Rabbit
    Application Key:
    • WB-Western Blotting 
    • IP-Immunoprecipitation 
    Species Cross-Reactivity Key:
    • H-Human 

    Product Information

    Product Usage Information

    Application Dilution
    Western Blotting 1:1000
    Immunoprecipitation 1:50

    Storage

    Supplied in 10 mM sodium HEPES (pH 7.5), 150 mM NaCl, 100 µg/ml BSA and 50% glycerol. Store at –20°C. Do not aliquot the antibody.

    Protocol

    Specificity / Sensitivity

    Eg5 Antibody recognizes endogenous levels of total Eg5 protein.

    Species Reactivity:

    Human

    Source / Purification

    Polyclonal antibodies are produced by immunizing animals with a synthetic peptide corresponding to residues near the carboxy terminus of human Eg5 protein. Antibodies are purified by protein A and peptide affinity chromatography.

    Background

    Eg5 (also called kinesin-like protein 11 or Kif11) belongs to the kinesin-like family of motor proteins important in chromosome positioning, centrosome separation, and mitotic spindle formation. Phosphorylation of Eg5 by mitotic kinases regulates its activity by modulating its association with microtubules (1,2). Because anti-mitotic chemotherapeutic drugs, such as taxanes, target microtubules and have pleiotropic and sometimes toxic effects, drugs that target microtubule-associated proteins such as Eg5 are currently in development (3-5).
    For Research Use Only. Not For Use In Diagnostic Procedures.
    Cell Signaling Technology is a trademark of Cell Signaling Technology, Inc.
    All other trademarks are the property of their respective owners. Visit our Trademark Information page.